» Articles » PMID: 20235210

Predictors for Remission in Rheumatoid Arthritis Patients: A Systematic Review

Overview
Specialty Rheumatology
Date 2010 Mar 18
PMID 20235210
Citations 59
Authors
Affiliations
Soon will be listed here.
Abstract

Objective: To summarize the potential predictors of remission in patients with rheumatoid arthritis (RA).

Methods: We performed a systematic review of prognostic studies that identified the predictors of remission in RA patients. Studies were identified in Medline, EMBase, and the Cochrane Registry, and by hand search. We included only studies performing multivariate analysis.

Results: A total of 18 studies from 2,062 citations were included. The following variables were found to be the independent predictors of RA remission: male sex; young age; late-onset RA; short disease duration; nonsmoker; low baseline disease activity; mild functional impairment; low baseline radiographic damage; absence of rheumatoid factor and anti-citrullinated peptide; low serum level of acute-phase reactant, interleukin-2, and RANKL at baseline; MTHFR 677T alleles and 1298C alleles in the methotrexate (MTX)-treated patients; magnetization transfer ratio 2756A allele +/- either the SLC 19A180A allele or the TYMS 3R-del6 haplotype in the MTX plus sulfasalazine combination-treated patients; early treatment with nonbiologic disease-modifying antirheumatic drug (DMARD) combinations; the use of anti-tumor necrosis factor (anti-TNF); the concurrent use of DMARDs in anti-TNF-treated patients; and moderate or good response to treatments at the first 6 months. The magnitude of the association in the individual predictor was diverse among the studies depending on the patient characteristics, the study characteristics, and the variables used to adjust for in the models.

Conclusion: A number of independent predictors of remission, i.e., baseline clinical and laboratory characteristics and genetic markers, were summarized. The predictive value of prognostic factors recently identified needs to be confirmed.

Citing Articles

Effect of disease duration on the use of tofacitinib: a real-world study in elderly patients with rheumatoid arthritis.

Wang X, Yang J, Yu L, Zhang J, Zhang X, Shen H Clin Rheumatol. 2024; 43(9):2807-2815.

PMID: 39093523 DOI: 10.1007/s10067-024-07084-2.


PERFECTRA: a pragmatic, multicentre, real-life study comparing treat-to-target strategies with baricitinib versus TNF inhibitors in patients with active rheumatoid arthritis after failure on csDMARDs.

van de Laar C, Oude Voshaar M, Ten Klooster P, Tedjo D, Bos R, Jansen T RMD Open. 2024; 10(2).

PMID: 38816210 PMC: 11328659. DOI: 10.1136/rmdopen-2024-004291.


Predicting anti-TNF treatment response in rheumatoid arthritis: An artificial intelligence-driven model using cytokine profile and routine clinical practice parameters.

Valdivieso Shephard J, Alvarez Robles E, Camara Hijon C, Hernandez Breijo B, Novella-Navarro M, Bogas Schay P Heliyon. 2024; 10(1):e22925.

PMID: 38163219 PMC: 10754867. DOI: 10.1016/j.heliyon.2023.e22925.


Impact of early age at menopause on disease outcomes in postmenopausal women with rheumatoid arthritis: a large observational cohort study of Korean patients with rheumatoid arthritis.

Park E, Kang E, Lee Y, Ha Y RMD Open. 2023; 9(1).

PMID: 36792311 PMC: 9933755. DOI: 10.1136/rmdopen-2022-002722.


Late-onset rheumatoid arthritis has a similar time to remission as younger-onset rheumatoid arthritis: results from the Ontario Best Practices Research Initiative.

Li X, Cesta A, Movahedi M, Bombardier C Arthritis Res Ther. 2022; 24(1):255.

PMID: 36401335 PMC: 9675233. DOI: 10.1186/s13075-022-02952-1.